AR076030A1 - Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso - Google Patents
Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de usoInfo
- Publication number
- AR076030A1 AR076030A1 ARP100101080A ARP100101080A AR076030A1 AR 076030 A1 AR076030 A1 AR 076030A1 AR P100101080 A ARP100101080 A AR P100101080A AR P100101080 A ARP100101080 A AR P100101080A AR 076030 A1 AR076030 A1 AR 076030A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- sequence
- seq
- methods
- immunocate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente solicitud se refiere a composiciones del tema utiles para el tratamiento del tumor hematopoyético en los mamíferos y a los métodos que usan estas composiciones para lo mismo. Reivindicacion 1: Un anticuerpo anti-FcRH5 que comprende: (a) al menos una secuencia de HVR seleccionada del grupo que consiste en: (i) HVR-L1 que comprende la secuencia KASQNVGSNVA (SEQ ID Ns:28), (ii) HVR-L2 que comprende la secuencia SASYRYS (SEQ ID Ns:29), (iii) HVR-L3 que comprende la secuencia QQYKTWT (SEQ ID Ns:30), (iv) HVR-H1 que comprende la secuencia GYTFTNYGMN (SEQ ID Ns:37), (v) HVR-H2 que comprende la secuencia NTYTGEPTYTDDFKG (SEQ ID Ns:38), (vi) HVR-H3 que comprende la secuencia ARRSIPYYYAMDY (SEQ ID Ns:39); y (b) al menos una variante de HVR, en donde la variante de HVR comprende la modificacion de al menos un residuo de la secuencia descripta en la SEQ ID Ns: 28, 29, 30, 37, 38 o 39.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21175409P | 2009-04-01 | 2009-04-01 | |
US16621409P | 2009-04-02 | 2009-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076030A1 true AR076030A1 (es) | 2011-05-11 |
Family
ID=42236394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101080A AR076030A1 (es) | 2009-04-01 | 2010-03-31 | Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso |
Country Status (19)
Country | Link |
---|---|
US (2) | US8362213B2 (es) |
EP (1) | EP2414395A1 (es) |
JP (2) | JP6099976B2 (es) |
KR (1) | KR20120003478A (es) |
CN (1) | CN102369218B (es) |
AR (1) | AR076030A1 (es) |
AU (1) | AU2010232682A1 (es) |
BR (1) | BRPI1012560A2 (es) |
CA (1) | CA2756988A1 (es) |
CL (1) | CL2011002418A1 (es) |
HK (1) | HK1166805A1 (es) |
IL (1) | IL215404A0 (es) |
MX (1) | MX2011010265A (es) |
PE (1) | PE20120877A1 (es) |
RU (2) | RU2016110891A (es) |
SG (1) | SG174930A1 (es) |
TW (1) | TW201039846A (es) |
WO (1) | WO2010114940A1 (es) |
ZA (1) | ZA201107128B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1012676A2 (pt) | 2009-04-01 | 2016-04-05 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
RU2016110891A (ru) | 2009-04-01 | 2018-11-27 | Дженентек, Инк. | Антитела к fcrh5, их иммуноконъюгаты и способы их применения |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
CN113527414A (zh) * | 2011-05-27 | 2021-10-22 | Ambrx公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
MX368966B (es) | 2011-06-10 | 2019-10-23 | Mersana Therapeutics Inc | Conjugados de proteina-polimero-farmaco. |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
MX2015010146A (es) * | 2013-02-08 | 2016-05-31 | Novartis Ag | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. |
KR102121638B1 (ko) | 2013-03-29 | 2020-06-10 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Wt1 항원 펩티드 콘쥬게이트 백신 |
US10588952B2 (en) | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
EP3015116B1 (en) * | 2013-06-24 | 2020-02-26 | ABLBio | Antibody-drug conjugate having improved stability and use thereof |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN115068626A (zh) | 2013-10-11 | 2022-09-20 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
PL3083689T3 (pl) * | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
KR20170108946A (ko) | 2014-12-05 | 2017-09-27 | 메모리얼 슬로안-케터링 캔서 센터 | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 |
CN108064246A (zh) * | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | 抗cd3抗体及び使用方法 |
JP6996983B2 (ja) | 2015-06-16 | 2022-02-21 | ジェネンテック, インコーポレイテッド | 抗cll-1抗体及び使用方法 |
EP4299073A3 (en) | 2015-06-16 | 2024-03-27 | F. Hoffmann-La Roche AG | Humanized and affinity matured antibodies to fcrh5 and methods of use |
MY197441A (en) | 2015-12-04 | 2023-06-19 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and method of use |
JPWO2017188346A1 (ja) * | 2016-04-27 | 2019-02-28 | 国立大学法人 東京大学 | マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法 |
BR112018076263A2 (pt) * | 2016-06-17 | 2019-03-26 | Magenta Therapeutics, Inc. | composições e métodos para a depleção de células |
TWI791471B (zh) | 2016-11-15 | 2023-02-11 | 美商建南德克公司 | 用於用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
TWI804499B (zh) * | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
CA3072153A1 (en) | 2017-08-10 | 2019-02-14 | Sumitomo Dainippon Pharma Co., Ltd. | Antibody-drug conjugates including hemiasterlin derivative |
TWI799438B (zh) * | 2017-08-10 | 2023-04-21 | 日商住友製藥股份有限公司 | 半星芒體衍生物及此等之抗體藥物複合體 |
US10766613B2 (en) * | 2017-11-28 | 2020-09-08 | Textron Innovations Inc. | System and method for rotorcraft-weight-on-wheels flight state transition control |
AU2019218959A1 (en) | 2018-02-08 | 2020-09-03 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
EP3826678A4 (en) * | 2018-07-25 | 2022-06-15 | Northeastern University | SELECTIVE SCREENING OF ANTIMICROBIAL COMPOUNDS |
IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
EP3897637A1 (en) | 2018-12-20 | 2021-10-27 | Novartis AG | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20220125941A1 (en) * | 2019-02-13 | 2022-04-28 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof |
EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
CN113329792A (zh) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
CA3145301A1 (en) * | 2019-07-08 | 2021-01-14 | Imcare Biotech, Llc. | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
US20240043512A1 (en) | 2019-09-11 | 2024-02-08 | Imcare Biotech, Llc | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
CA3158579A1 (en) | 2019-12-18 | 2021-06-24 | Pranjali DALVI | Heavy chain antibodies binding to cd38 |
BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
CA3218362A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
WO2023078968A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
US20230406930A1 (en) * | 2022-04-13 | 2023-12-21 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
CN116199772B (zh) * | 2022-11-16 | 2023-10-17 | 怡道生物科技(苏州)有限公司 | Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
KR100332254B1 (ko) | 1993-10-01 | 2002-09-27 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규인펩티드유도체 |
US7074897B2 (en) | 1997-06-16 | 2006-07-11 | Genentech, Inc. | Pro943 polypeptides |
US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
EP2316843B1 (en) * | 1999-11-29 | 2015-10-14 | The Trustees of Columbia University in the City of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
US7105149B1 (en) * | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2002102854A2 (en) * | 2001-06-20 | 2002-12-27 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
ATE486092T1 (de) | 2001-09-18 | 2010-11-15 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
US7888478B2 (en) * | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US7858330B2 (en) * | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
WO2005117986A2 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody drug conjugates and methods |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
PT2489364E (pt) * | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
JP4658967B2 (ja) | 2003-12-24 | 2011-03-23 | ジェネンテック, インコーポレイテッド | 造血系起源の腫瘍の治療のための組成物と方法 |
DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
US7999077B2 (en) | 2004-09-30 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IRTA2 antibodies and methods of use |
US7947839B2 (en) * | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
WO2006076691A2 (en) * | 2005-01-12 | 2006-07-20 | Medarex, Inc. | Irta-2 antibodies and their uses |
DK2135881T3 (da) * | 2005-06-20 | 2011-12-05 | Genentech Inc | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor |
WO2008109533A2 (en) * | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
RU2016110891A (ru) | 2009-04-01 | 2018-11-27 | Дженентек, Инк. | Антитела к fcrh5, их иммуноконъюгаты и способы их применения |
BRPI1012676A2 (pt) | 2009-04-01 | 2016-04-05 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
-
2010
- 2010-03-31 RU RU2016110891A patent/RU2016110891A/ru not_active Application Discontinuation
- 2010-03-31 RU RU2011144119/10A patent/RU2583270C2/ru not_active IP Right Cessation
- 2010-03-31 MX MX2011010265A patent/MX2011010265A/es active IP Right Grant
- 2010-03-31 US US12/751,791 patent/US8362213B2/en not_active Expired - Fee Related
- 2010-03-31 TW TW099109950A patent/TW201039846A/zh unknown
- 2010-03-31 KR KR1020117025849A patent/KR20120003478A/ko active IP Right Grant
- 2010-03-31 CA CA2756988A patent/CA2756988A1/en not_active Abandoned
- 2010-03-31 BR BRPI1012560A patent/BRPI1012560A2/pt not_active IP Right Cessation
- 2010-03-31 EP EP10711526A patent/EP2414395A1/en not_active Ceased
- 2010-03-31 AU AU2010232682A patent/AU2010232682A1/en not_active Abandoned
- 2010-03-31 CN CN201080014347.1A patent/CN102369218B/zh not_active Expired - Fee Related
- 2010-03-31 JP JP2012503682A patent/JP6099976B2/ja not_active Expired - Fee Related
- 2010-03-31 AR ARP100101080A patent/AR076030A1/es not_active Application Discontinuation
- 2010-03-31 PE PE2011001751A patent/PE20120877A1/es not_active Application Discontinuation
- 2010-03-31 SG SG2011069895A patent/SG174930A1/en unknown
- 2010-03-31 WO PCT/US2010/029521 patent/WO2010114940A1/en active Application Filing
-
2011
- 2011-09-27 IL IL215404A patent/IL215404A0/en unknown
- 2011-09-29 ZA ZA2011/07128A patent/ZA201107128B/en unknown
- 2011-09-30 CL CL2011002418A patent/CL2011002418A1/es unknown
-
2012
- 2012-07-26 HK HK12107358.7A patent/HK1166805A1/xx not_active IP Right Cessation
- 2012-11-09 US US13/673,565 patent/US9017951B2/en not_active Expired - Fee Related
-
2015
- 2015-08-27 JP JP2015168182A patent/JP2016028052A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL215404A0 (en) | 2011-12-29 |
TW201039846A (en) | 2010-11-16 |
US9017951B2 (en) | 2015-04-28 |
CL2011002418A1 (es) | 2012-03-16 |
JP2012522513A (ja) | 2012-09-27 |
AU2010232682A1 (en) | 2011-11-10 |
JP2016028052A (ja) | 2016-02-25 |
US8362213B2 (en) | 2013-01-29 |
BRPI1012560A2 (pt) | 2016-07-26 |
JP6099976B2 (ja) | 2017-03-29 |
EP2414395A1 (en) | 2012-02-08 |
ZA201107128B (en) | 2012-12-27 |
US20110171125A1 (en) | 2011-07-14 |
CA2756988A1 (en) | 2010-10-07 |
KR20120003478A (ko) | 2012-01-10 |
RU2583270C2 (ru) | 2016-05-10 |
SG174930A1 (en) | 2011-11-28 |
RU2016110891A (ru) | 2018-11-27 |
HK1166805A1 (en) | 2012-11-09 |
MX2011010265A (es) | 2011-10-11 |
CN102369218A (zh) | 2012-03-07 |
PE20120877A1 (es) | 2012-08-06 |
WO2010114940A1 (en) | 2010-10-07 |
CN102369218B (zh) | 2014-07-16 |
US20130089497A1 (en) | 2013-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076030A1 (es) | Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso | |
AR076029A1 (es) | Anticuerpos anti- fcrh5 (receptor de translocacion asociado a la superfamilia de inmunoglobulina) e inmunoconjugados y metodos de uso | |
AR067543A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso | |
AR067544A1 (es) | Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos | |
AR065271A1 (es) | Anticuerpos anti-robo4 y sus usos | |
ES2628108T3 (es) | Anticuerpos multiespecíficos | |
PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
PE20141722A1 (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t | |
ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
WO2013003680A8 (en) | Anti-c-met antibody formulations | |
RU2011134500A (ru) | Антитела и иммуноконъюгаты и их применения | |
AR084456A1 (es) | Anticuerpo anti-pcsk9 y metodos de uso | |
AR096364A1 (es) | Anticuerpos receptores de antitransferina y métodos de uso | |
PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
PE20150211A1 (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
PE20141114A1 (es) | Anticuerpos anti-mesotelina e inmunoconjugados | |
AR059432A1 (es) | Anticuerpos anti-fgf19 y metodos que usan estos | |
RS53942B1 (en) | Antibodies and Immunoconjugates and Their Use | |
RU2017128882A (ru) | Антитела к биотину и способы их применения | |
PE20120080A1 (es) | Anticuerpos anti-notch2 y metodos de uso | |
AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
AR076662A1 (es) | Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |